Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated a Neutral rating on Collegium Pharmaceutical (NASDAQ:COLL) and lowered the price target from $39 to $37.
August 09, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has reiterated a Neutral rating on Collegium Pharmaceutical and lowered the price target from $39 to $37.
The lowered price target from $39 to $37 suggests a less optimistic outlook for Collegium Pharmaceutical, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100